| Autor: |
Niemann CU; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, DK-2100 Copenhagen, Denmark. Electronic address: carsten.utoft.niemann@regionh.dk., Kater AP; Amsterdam University Medical Centers, Cancer Center Amsterdam, University of Amsterdam, Amsterdam, Netherlands. |
| Abstrakt: |
Competing Interests: CUN received consultancy fees and research funding from AbbVie, Janssen, Octapharma, and AstraZeneca; received research funding from Novo Nordisk Foundation, Danish Cancer Society, and Alfred Benzon foundation; and received consultancy fees from CSL Behring, Genmab, Takeda, Eli Lilly, and Beigene. APK received research funding (personal fees) from AbbVie, AstraZeneca, BMS, Janssen, and Roche/Genentech; patent royalties (personal fees) from Janssen and LAVA; speakers’ fees (personal fees) from AbbVie, AstraZeneca, and Janssen; and served on the board of directors or advisory committees for AstraZeneca, BMS, Roche/Genentech, Janssen, AbbVie, and LAVA. |
